Metastatic Biliary Tract Cancer - Pipeline Review, H1 2015


#246276

49pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, Metastatic Biliary Tract Cancer Pipeline Review, H1 2015, provides an overview of the Metastatic Biliary Tract Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Biliary Tract Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Biliary Tract Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Biliary Tract Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Biliary Tract Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Metastatic Biliary Tract Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Biliary Tract Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Biliary Tract Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Biliary Tract Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 3
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Biliary Tract Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Biliary Tract Cancer - Overview 7
Pipeline Products for Metastatic Biliary Tract Cancer - Comparative Analysis 8
Metastatic Biliary Tract Cancer - Therapeutics under Development by Companies 9
Metastatic Biliary Tract Cancer - Pipeline Products Glance 10
Clinical Stage Products 10
Metastatic Biliary Tract Cancer - Products under Development by Companies 11
Metastatic Biliary Tract Cancer - Companies Involved in Therapeutics Development 12
AstraZeneca PLC 12
GlaxoSmithKline plc 13
Novartis AG 14
OncoTherapy Science, Inc. 15
Metastatic Biliary Tract Cancer - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
binimetinib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
OCV-C01 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
selumetinib sulfate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
trametinib dimethyl sulfoxide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Metastatic Biliary Tract Cancer - Recent Pipeline Updates 38
Metastatic Biliary Tract Cancer - Discontinued Products 47

Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

Number of Products under Development for Metastatic Biliary Tract Cancer, H1 2015 7
Number of Products under Development for Metastatic Biliary Tract Cancer - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Products under Development by Companies, H1 2015 11
Metastatic Biliary Tract Cancer - Pipeline by AstraZeneca PLC, H1 2015 12
Metastatic Biliary Tract Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 13
Metastatic Biliary Tract Cancer - Pipeline by Novartis AG, H1 2015 14
Metastatic Biliary Tract Cancer - Pipeline by OncoTherapy Science, Inc., H1 2015 15
Assessment by Monotherapy Products, H1 2015 16
Assessment by Combination Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 22
Number of Products by Stage and Molecule Type, H1 2015 24
Metastatic Biliary Tract Cancer Therapeutics - Recent Pipeline Updates, H1 2015 38
Metastatic Biliary Tract Cancer - Discontinued Products, H1 2015 47

Number of Products under Development for Metastatic Biliary Tract Cancer, H1 2015 7
Number of Products under Development for Metastatic Biliary Tract Cancer - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Assessment by Monotherapy Products, H1 2015 16
Number of Products by Top 10 Targets, H1 2015 18
Number of Products by Stage and Top 10 Targets, H1 2015 19
Number of Products by Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 22
Number of Products by Top 10 Molecule Types, H1 2015 23
Number of Products by Stage and Top 10 Molecule Types, H1 2015 24